Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Wall Street is looking for Inogen to make a big splash with its new Inogen At Home oxygen concentration system, which won FDA clearance today.
The new device weighs in at 18 pounds, shaving 10 to 20 pounds off of competing devices, makes less noise and uses less power than any other device in its class, Inogen said. The at-home device rounds out Inogen’s highly praised portfolio of portable systems. Read more
NeuroMetrix got a major Wall Street boost today after announcing Japanese market approval for its NC-stat DPNCheck test for diabetic peripheral neuropathy.
The NC-stat DPNCheck is an early detection system for DPN, which affects more than half of patients with diabetes, making it the most common complication of the disease. DPN can cause pain, increase risk of falls and is the “primary trigger” for diabetic foot ulcers that can lead to amputations, NeuroMetrix said. Read more
Medtronic said yesterday that Geoff Martha, senior vice president for strategy & business development, is being promoted to chief integration officer ahead of Medtronic’s $43 billion acquisition of Covidien.
In a June 24 letter to Medtronic employees, CEO Omar Ishrak said Martha will serve as the primary liaison between the 2 medical device companies. Read more